Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden, and Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. The company was incorporated in 2020 and is based in Lund, Sweden.

Newbury Pharmaceuticals AB (publ)

Newbury Pharma is a rapidly growing hybrid pharmaceutical company focused on specialty prescription drugs, innovation, and branded products. The company aims to impact society positively by bringing products and technology that contribute to healthcare systems and patient wellbeing. Newbury Pharmaceuticals is developing a pipeline of proprietary and licensed products with a focus on oncology, rare diseases, and neurology.

Metric
Company Name	Newbury Pharmaceuticals AB (publ)
Symbol	NEWBRY
MSH ID	COM:NEWBURYPHARMA
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Country	SE
Stage
Employee Count	5
Website	newburypharma.com
LinkedIn
Founders

Metric
Market Cap	8.35M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	3.37M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.47M
EBITDA	-1.13M
Operating Income	-1.29M
Net Income	-1.41M
EPS	-0.07
Diluted EPS	-0.07
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.42
Operating Profit Margin	-0.73
EBITDA Margin	-0.34
Net Profit Margin	-0.76
Return on Equity	-0.36
Return on Assets	-0.21
Return on Capital Employed	-0.32

NEWB

COM:NEWBURYPHARMA

Newbury Pharma

Last Close

3.32

25/11 08:40

Market Cap

91.21M

Beta: -

Volume Today

4.70K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-4.05
P/B Ratio	1.72
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.48
EV Multiple	-4.58

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	212.97
Operating Cycle	212.97
Cash Conversion Cycle	212.97
Asset Turnover	0.27

Metric
Operating Cash Flow	-2.17M
Free Cash Flow	-2.17M
Cash Flow to Debt
Operating Cash Flow/Sales	-1.13
Free Cash Flow Yield	-0.30

Metric
Cash & Equivalents	1.40M
Accounts Receivable
Inventory	457.01K
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio	1.13
Quick Ratio	1.30

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue	0.14